Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Greig

Showing results (161-170 of 332) with videos related to

Pageof 34
Sort By:
Translational Psychiatry|February 19, 2020
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's diseaseBalmiki Ray, Bryan Maloney, Kumar Sambamurti, et al.
Journal of Neuroscience Research|May 16, 2003
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and ironTracyAnn Perry, Debomoy K Lahiri, Kumar Sambamurti, et al.
Bioorganic & Medicinal Chemistry|February 24, 2018
Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activitiesWeiming Luo, David Tweedie, Shaunna L Beedie, et al.
Journal of Alzheimer'S Disease : JAD|September 22, 2006
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserineMohammad A Kamal, Peter Klein, Qian-Sheng Yu, et al.
Annals of the New York Academy of Sciences|February 1, 2005
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated regionAmanda Venti, Tony Giordano, Paul Eder, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 13, 2026
A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesteraseIason Tzieras, Apostolos Manolopoulos, David Tweedie, et al.
Journal of Neuroscience Research|February 14, 2013
3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammationJeong Seon Yoon, Jong-Hwan Lee, David Tweedie, et al.
Epigenomics|March 8, 2016
Transgenerational latent early-life associated regulation unites environment and genetics across generationsDebomoy K Lahiri, Bryan Maloney, Baindu L Bayon, et al.
Cell Transplantation|June 7, 2018
Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After StrokeFlavia Turcato, Paul Kim, Austin Barnett, et al.
Journal of Alzheimer'S Disease : JAD|April 24, 2010
Differential accumulation of secreted AbetaPP metabolites in ocular fluidsAnnamalai Prakasam, Anusuya Muthuswamy, Zsolt Ablonczy, et al.
Pageof 34

Showing results (161-170 of 332) with videos related to

Sort By:
Pageof 34
Translational Psychiatry|February 19, 2020
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's diseaseBalmiki Ray, Bryan Maloney, Kumar Sambamurti, et al.
Journal of Neuroscience Research|May 16, 2003
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and ironTracyAnn Perry, Debomoy K Lahiri, Kumar Sambamurti, et al.
Bioorganic & Medicinal Chemistry|February 24, 2018
Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activitiesWeiming Luo, David Tweedie, Shaunna L Beedie, et al.
Journal of Alzheimer'S Disease : JAD|September 22, 2006
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserineMohammad A Kamal, Peter Klein, Qian-Sheng Yu, et al.
Annals of the New York Academy of Sciences|February 1, 2005
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated regionAmanda Venti, Tony Giordano, Paul Eder, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 13, 2026
A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesteraseIason Tzieras, Apostolos Manolopoulos, David Tweedie, et al.
Journal of Neuroscience Research|February 14, 2013
3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammationJeong Seon Yoon, Jong-Hwan Lee, David Tweedie, et al.
Epigenomics|March 8, 2016
Transgenerational latent early-life associated regulation unites environment and genetics across generationsDebomoy K Lahiri, Bryan Maloney, Baindu L Bayon, et al.
Cell Transplantation|June 7, 2018
Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After StrokeFlavia Turcato, Paul Kim, Austin Barnett, et al.
Journal of Alzheimer'S Disease : JAD|April 24, 2010
Differential accumulation of secreted AbetaPP metabolites in ocular fluidsAnnamalai Prakasam, Anusuya Muthuswamy, Zsolt Ablonczy, et al.
Pageof 34